Total Voting Rights
Hemogenyx Pharmaceuticals plc
(“Hemogenyx” or the “Company”)
Total Voting Rights
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company consists of 397,253,969 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 397,253,969.
The figure of 397,253,969 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
|Hemogenyx Pharmaceuticals plc||hemogenyx.com|
|Dr Vladislav Sandler, Chief Executive Officer & Co-Founderemail@example.com|
|Peter Redmond, Non-Executive Director|
|SP Angel Corporate Finance LLP||Tel: +44 (0)20 3470 0470|
|Matthew Johnson, Vadim Alexandre, Soltan Tagiev|
|Peterhouse Capital Limited||Tel: +44 (0)20 7469 0930|
|Lucy Williams, Duncan Vasey, Charles Goodfellow|
|US Media enquiries||Tel: +1 (323) 646-3249|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc (“Hemogenyx”) is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.